Kawakami Satoru, Hyochi Nobuhiko, Yonese Junji, Yano Masataka, Fujii Yasuhisa, Kageyama Yukio, Fukui Iwao, Kihara Kazunori
Department of Urology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Tokyo 113-8519, Japan.
Int J Clin Oncol. 2006 Apr;11(2):127-32. doi: 10.1007/s10147-005-0547-0.
Although an increasing number of men present with stage T1c prostate cancer, the optimal biopsy strategy for detecting stage T1c disease still remains to be defined. The aim of this study was to explore an efficient first-time biopsy scheme for detecting stage T1c and T2 prostate cancer.
A transrectal ultrasound-guided systematic three-dimensional 26-core (3D26) biopsy comprising 12 transrectal and 14 transperineal sampling sites was performed in 321 men with median prostate-specific antigen (PSA) level of 6.0 ng/ml in the first-time biopsy setting. By analyzing site-specific cancer detection rates, we determined the best combination of transperineal and transrectal sampling sites.
Prostate cancer was detected in 109 of the 321 men (34%) with a major complication rate of 0.6%. 3D26 biopsy significantly improved cancer detectability by 60% relative to the conventional transrectal sextant (TR6) biopsy. Improvement was significant in 263 men with normal digital rectal examination (DRE) (85%, P = 0.0004) but not in 58 men with abnormal DRE (22%, P = 0.18). The mean Gleason score of the 41 cancers without a positive core within the TR6 sites was marginally lower than that of 68 cancers with a positive core within the TR6 sites (P = 0.04). Recursive partitioning revealed that a three-dimensional 14-core (transrectal 8-core plus transperineal 6-core) and a three-dimensional 8-core (transrectal 4-core plus transperineal 4-core) biopsies could detect more than 95% of stage T1c and T2 cancers with a minimum number of cores, respectively.
We propose a three-dimensional 14-core and a three-dimensional 8-core biopsy as efficient first-time biopsy schemes to detect stage T1c and T2 prostate cancer, respectively.
尽管越来越多的男性被诊断为T1c期前列腺癌,但检测T1c期疾病的最佳活检策略仍有待确定。本研究的目的是探索一种有效的初次活检方案,用于检测T1c期和T2期前列腺癌。
对321名男性进行经直肠超声引导下的系统性三维26针(3D26)活检,其中包括12个经直肠和14个经会阴采样点,这些男性在初次活检时前列腺特异性抗原(PSA)水平的中位数为6.0 ng/ml。通过分析特定部位的癌症检出率,我们确定了经会阴和经直肠采样点的最佳组合。
321名男性中有109名(34%)检测出前列腺癌,主要并发症发生率为0.6%。与传统的经直肠六分区(TR6)活检相比,3D26活检显著提高了癌症检出率60%。在263名直肠指检(DRE)正常的男性中改善显著(85%,P = 0.0004),但在58名DRE异常的男性中无显著改善(22%,P = 0.18)。在TR6部位无阳性针芯的41例癌症的平均Gleason评分略低于在TR6部位有阳性针芯的68例癌症(P = 0.04)。递归划分显示,三维14针(经直肠8针加经会阴6针)和三维8针(经直肠4针加经会阴4针)活检分别可以用最少的针芯数检测出超过95%的T1c期和T2期癌症。
我们提出三维14针和三维8针活检分别作为检测T1c期和T2期前列腺癌的有效初次活检方案。